Clinical trials: Grip
Mucopolysaccharidosis IVA, Morquio A Syndrome
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01697319
- Testing
- BMN 110
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- BioMarin Pharmaceutical
Occupational Therapy, Virtual Reality
Glove Rehabilitation Application for Stroke Patients
The University of Virginia (UVA) Director of Neurorehabilitation will lead GRASP randomized, controlled efficacy trials. The study will involve employment of the GRASP system in three one-hour sessions per week over eight weeks…
- Trial name
- GRASP (NCT03872466)
- Testing
- GRASP HEP, Usual Care Treatment (UCT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barron Associates, Inc.
Cachexia
Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not…
- Trial name
- VT-122 (NCT00527319)
- Testing
- VT-122 low dose, VT-122 high dose
- Where
- 8 sites in United States, India
- Volunteers
- 37 people
- Sponsor
- Vicus Therapeutics